Pharmaceuticals 5 July 2026

Telix Pharmaceuticals trails ASX 200 by 8.3 points; Japan remains beyond guidance

Telix Pharmaceuticals Ltd opened Monday trading at A$14.91, its last available price. Shares dropped 4.48% on Friday. Australia's cash market was active, though Google Finance continued to display Friday’s data.

20 July 2026

ASX News·ASX:TLX·NASDAQ:TLX·Pharmaceuticals·Stock Market

Viking Therapeutics (NASDAQ:VKTX) stock maintains Phase 3 outlook despite 4.6% fall over the week

Viking Therapeutics, Inc. declined by 4.6% over the past week. Nonetheless, its initial cash-adjusted valuation remained 86% higher than that of Structure Therapeutics Inc..

18 July 2026

NASDAQ:GPCR·NASDAQ:VKTX·Pharmaceuticals

Iovance Biotherapeutics (NASDAQ:IOVA) shares jump 18% as Amtagvi sales test approaches

Iovance Biotherapeutics, Inc. gained approximately $344 million in equity value last week, representing 95.5% of its $360 million midpoint for full-year revenue guidance. U.S. markets were closed on Saturday. The company's shares ended Friday at $5.00.

18 July 2026

NASDAQ:IOVA·Pharmaceuticals·Stock Market

Iovance (NASDAQ:IOVA) gains after $89.7 million stock sale

Iovance shares surge as attention shifts to Amtagvi’s second-half sales target

Iovance finished Thursday at $4.66, gaining 10.2% from July 10. Nasdaq’s regular session had ended at the dateline, while premarket trading remained open.

17 July 2026

NASDAQ:IOVA·Pharmaceuticals·Stock Market

GSK plc (LON:GSK) drops after cough medicine blow wipes £2.4 billion off market value

GSK plc shed roughly £2.36 billion in market value on Friday after mixed phase III data halted the camlipixant chronic-cough programme. The decline surpassed GSK's 2023 acquisition cost for BELLUS by approximately £765 million.

17 July 2026

LON:GSK·Pharmaceuticals·Stock Market

TrumpRx’s 800-Drug List Masks Modest Pharma Price Exposure

TrumpRx currently includes around 10% of the branded drug portfolios offered by pharmaceutical companies taking part in the program, well below the widely cited figure of more than 800 medicines.

17 July 2026

NASDAQ:GILD·NYSE:LLY·NYSE:PFE·Pharmaceuticals

Eli Lilly (NYSE:LLY) Shares Rise After Atai Partnership Could Unlock $1 Billion in Milestones

NEW YORK, July 16, 2026, 5:08 p.m. EDT – Shares of Eli Lilly edged higher on Thursday after the drugmaker announced a deal with Atai Life Sciences, a partnership that may generate up to $1 billion in milestone payments.

16 July 2026

NASDAQ:ATAI·NYSE:LLY·Pharmaceuticals·Stock Market

Health stocks today: Abbott (NYSE: ABT) jumps 11% as insurers split

Abbott Laboratories jumped 10.9%, lifting the XLV healthcare benchmark on Thursday. Managed-care shares moved in both directions.

16 July 2026

NYSE:ABT·NYSE:ELV·NYSE:UNH·Pharmaceuticals

AtaiBeckley (NASDAQ: ATAI) stock jumps on Lilly deal as market discounts milestones

AtaiBeckley Inc. jumped about 31% to $7.04 on Thursday. Eli Lilly and Co. agreed to buy the company for up to $3.8 billion.

16 July 2026

NASDAQ:ATAI·NYSE:LLY·Pharmaceuticals·Stock Market

Pfizer (NYSE:PFE) Faces New Patent Claim After $96 Billion in COVID Vaccine Revenue

Pfizer Inc. shares rose 2.35% to $24.82 on Wednesday after Sanofi SA brought a new patent case over the Comirnaty COVID-19 vaccine. The gain suggests investors viewed the complaint as a possible charge against past vaccine earnings, rather than an immediate block on sales.

15 July 2026

NASDAQ:SNY·NYSE:PFE·Pharmaceuticals

Johnson & Johnson leans on two main drugs for almost all Q2 sales growth

Johnson & Johnson mostly leaned on Tremfya and Darzalex for almost all of its Q2 sales growth, according to a review of results from the healthcare group. This leaves investors asking how much depth backs up J&J’s higher 2026 guidance.

15 July 2026

NYSE:JNJ·Pharmaceuticals

Pfizer (NYSE:PFE) scores FDA approval but Wall Street reaction muted

U.S. markets are shut for the weekend, so investors are waiting to see if Friday’s FDA approval of Padcev with Keytruda will do much for Pfizer Inc.’s earnings. So far, no big move. Pfizer slipped 0.33% to $24.17 on Friday, down 0.62% since the July 2 close before the July 4 break. The S&P 500 rose 1.2% last week. The FDA cleared the drug based on a 47% lower risk of recurrence, progression or death, which looks strong clinically. But investors want more proof that sales to bladder-cancer patients can make up for Pfizer’s patent losses.

12 July 2026

NYSE:MRK·NYSE:PFE·Pfizer News·Pharmaceuticals·Stock Market·TSE:4503

Biotech Stocks Face Big $15B Hit as Vertex, Ionis Skew Flat Weekly Tape

Biotech names Vertex Pharmaceuticals and Ionis Pharmaceuticals slumped after two big setbacks, wiping out about $14.8 billion in market value over the five sessions through Friday. That's going by Friday's share counts and using July 2 and July 10 close, even as a takeover target in the sector almost doubled.

11 July 2026

NASDAQ:IONS·NASDAQ:VRTX·Pharmaceuticals·Stock Market

Moderna Stock Sinks 11%; Its 24 Million-Dose EU Deal Has a No-Minimum Catch

Moderna Inc. shares fell 11.3% to $67.91 at 12:53 p.m. EDT on Friday, erasing about $3.4 billion in market value. The vaccine maker had traded as high as $78.47, leaving the stock 13.5% below its intraday peak.

10 July 2026

NASDAQ:MRNA·Pharmaceuticals·Stock Market

Eli Lilly (LLY) Hovers Near $1,200 as Focus Stays on $50 Obesity Drug Access

Eli Lilly grabbing headlines with its four-digit stock price and split plan, but there’s a messier reality for investors. The drugmaker is giving up higher net prices in order to sell a lot more units.

9 July 2026

NYSE:LLY·Pharmaceuticals·Stock Market

Agios Pharmaceuticals (NASDAQ:AGIO) pops as FDA review moves price above average target

Agios Pharmaceuticals soared Tuesday after the FDA granted its sickle-cell disease application priority review. Shares pushed through the average Wall Street price target before any official FDA decision.

7 July 2026

NASDAQ:AGIO·Pharmaceuticals·Stock Market

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) stock jumps as Phase 1 data puts cash-value biotech under heavy churn

Tvardi Therapeutics, Inc. jumped as much as 89% on Tuesday after the STAT3 drug developer reported Phase 1 data for TTI-109, but the harder market signal was volume. About 53.9 million shares changed hands by early afternoon, equal to 5.7 times the 9.38 million shares outstanding listed in its latest quarterly filing.

7 July 2026

NASDAQ:TVRD·Pharmaceuticals·Stock Market

Pfizer rebound keeps dividend stable, HSBC lowers upside by $23 billion

Pfizer Inc. traded up 1.7% at $24.13 as of 11:48 a.m. EDT Tuesday, recovering some ground after Monday’s 2.47% slide to $23.72. The stock’s loss on Monday stood out with the S&P 500 up 0.72% and the Dow up 0.29%, making it a clear underperformer, not just a victim of the broader market.

7 July 2026

Dividends·NYSE:PFE·Pharmaceuticals·Stock Market

Pfizer (NYSE:PFE) stuck near $24; 7% yield comes into view

Pfizer Inc. heads into this week after the stock managed to stop the steep drops, though buyers are still scarce. Shares ended Thursday at $24.32, just 3 cents above where they were on June 26. Over the last four sessions, 204.2 million shares moved, good for a 0.12% rise. That volume is around 3.6% of Pfizer’s diluted share count used in Q1 EPS calculations.

5 July 2026

Pharmaceuticals·Stock Market

Novo Nordisk (CPH:NOVO-B) rises, but volume stays light ahead of August results

Novo Nordisk A/S finished the week with a smaller rally than the rest of the Danish market. B shares closed Friday at DKK 326.90, dropping 1.54% on the day but still up 2.8% for the week. The OMX Copenhagen 25 gained 5.5% in the same period, so the stock lagged the benchmark by about 2.6 percentage points. Novo’s Friday volume hit 2.58 million shares, or 45% of its 65-day average, according to MarketWatch. For the week, turnover was 19.23 million shares, down from 25.66 million a week earlier. Investing.com reported the OMXC25 at 1,899.12 on Friday, up from 1,800.88 the previous week.

5 July 2026

CPH:NOVO-B·Earnings Reports·Pharmaceuticals·Stock Market

Pharmaceuticals 5 July 2026 - 20 July 2026